Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Public ClinicalTrials.gov record NCT02552212. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo. The primary objective is to demonstrate the efficacy of CZP in these patients.
Study identification
- NCT ID
- NCT02552212
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 317 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2015 (Actual)
- Primary completion
- May 2018 (Actual)
- Completion
- May 2020 (Actual)
- Last update posted
- Aug 18, 2022
2015 – 2020
United States locations
- U.S. sites
- 36
- U.S. states
- 20
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| As0006 125 | Birmingham | Alabama | — | — |
| As0006 120 | Scottsdale | Arizona | — | — |
| As0006 115 | Tucson | Arizona | — | — |
| As0006 155 | Beverly Hills | California | — | — |
| As0006 101 | Palm Desert | California | — | — |
| As0006 143 | San Francisco | California | — | — |
| As0006 160 | New Haven | Connecticut | — | — |
| As0006 117 | Daytona Beach | Florida | — | — |
| As0006 116 | DeBary | Florida | — | — |
| As0006 124 | Fort Lauderdale | Florida | — | — |
| As0006 133 | New Port Richey | Florida | — | — |
| As0006 138 | Plantation | Florida | — | — |
| As0006 134 | Tampa | Florida | — | — |
| As0006 106 | Vero Beach | Florida | — | — |
| As0006 148 | Atlanta | Georgia | — | — |
| As0006 137 | Idaho Falls | Idaho | — | — |
| As0006 102 | Cumberland | Maryland | — | — |
| As0006 141 | Cumberland | Maryland | — | — |
| As0006 111 | Wheaton | Maryland | — | — |
| As0006 127 | Boston | Massachusetts | — | — |
| As0006 147 | Worcester | Massachusetts | — | — |
| As0006 110 | Eagan | Minnesota | — | — |
| As0006 123 | Rochester | Minnesota | — | — |
| As0006 103 | St Louis | Missouri | — | — |
| As0006 114 | Brooklyn | New York | — | — |
| As0006 118 | Charlotte | North Carolina | — | — |
| As0006 149 | Oklahoma City | Oklahoma | — | — |
| As0006 105 | Portland | Oregon | — | — |
| As0006 108 | Duncansville | Pennsylvania | — | — |
| As0006 144 | Philadelphia | Pennsylvania | — | — |
| As0006 129 | Wyomissing | Pennsylvania | — | — |
| As0006 156 | Orangeburg | South Carolina | — | — |
| As0006 107 | Salt Lake City | Utah | — | — |
| As0006 104 | Seattle | Washington | — | — |
| As0006 158 | Manitowoc | Wisconsin | — | — |
| As0006 113 | Onalaska | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02552212, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2022 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02552212 live on ClinicalTrials.gov.